← Back to Search

Antioxidant

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Matrix Biomed, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 20
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing MBM-02, a drug that aims to treat recurring prostate cancer by blocking genes that help cancer cells survive in low oxygen conditions. The study will measure the drug's effectiveness through PSA levels and scans over several months.

Eligible Conditions
  • Prostate Cancer Recurrence
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 20
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 20 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reduction in Serum PSA
Secondary study objectives
PSA progression
Percent Change in PSA

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Cohort5Experimental Treatment1 Intervention
Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
Group II: Cohort 6Experimental Treatment1 Intervention
Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
Group III: Cohort 4Experimental Treatment1 Intervention
Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
Group IV: Cohort 3Experimental Treatment1 Intervention
Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
Group V: Cohort 2Experimental Treatment1 Intervention
Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
Group VI: Cohort 1Experimental Treatment1 Intervention
Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.

Find a Location

Who is running the clinical trial?

Matrix Biomed, Inc.Lead Sponsor
5 Previous Clinical Trials
195 Total Patients Enrolled
1 Trials studying Prostate Cancer
Prostate Oncology SpecialistsUNKNOWN
~12 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top